Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 323

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 323
---
 Ling Wang on May 8, 2023 (the “Gao & Wang Note”). |

| ● | On July 11, 2023, we issued a total of 3,336 restricted shares of common stock to the following directors and in the amounts listed: (i) Stephen Toovey (834 restricted shares of common stock), (ii) Charles Allen (834 restricted shares of common stock), (iii) Paul Field (834 restricted shares of common stock) and (iv) Cheryl Xu (834 restricted shares of common stock). |

| ● | On July 14, 2023, we issued a total of 2,438 restricted shares of our common stock to BioIntelect Pty Ltd as deferred equity compensation valued in the amount of $155,000. |

| ● | On July 14, 2023, we converted the entirety of debt owed to a noteholder to 17,912 shares of our common stock at the conversion price equal to the initial public offering price, of which were issued to Xu Yu. |

| ● | On July 14, 2023, we issued 92,362 restricted shares of common stock to Knight Therapeutics (Barbados) Inc.) (“Knight”) upon conversion of debt owed to Knight. |

| ● | On July 28, 2023, we issued 3,797 restricted shares of our common stock to Knight upon conversion of 2,162 shares of Series A Preferred Stock, at the conversion rate price detailed in Note 6 to the accompanying consolidated condensed financial statements. |

The issuances of shares of common stock listed above were deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities did not involve a public offering. II-2

| ● | On the effective date of our initial public offering registration statement,                                                            
 we issued 5,787 shares of our common stock to Mountjoy Trust as a result of the conversion of the Convertible Promissory Note we issued 
 to Mountjoy Trust on May 19, 2022 (the “Mountjoy Note”).                                                                                |

| ● | From October 2024 to January 2025, we issued an aggregate of 2,898,551                                                       
 shares of common stock upon the exercise of pre-funded warrants issued to investors in the September 2025 private placement. |

The issuance of the capital stock listed above was deemed exempt from registration under Section 4(a)(